2025年2月24日,周一盘中,Telix Pharmaceuticals(TLX.US)股价大涨10%,引发市场广泛关注。
此前,Telix公布了2024财年财报,财报显示公司2024财年净利润达到3293万美元,同比大涨851.73%。营业收入也同比增长54.79%至5.17亿美元,利润和收入双双大幅增长。
Telix是一家开发治疗和成像癌症的放射性药物的生物制药公司。其主打产品Illuccix用于前列腺癌成像,在美国已实现大规模商业化销售。财报数据反映了公司业务高速增长的良好态势,有力增强了市场对公司长期发展前景的信心,成为推动股价暴涨的主要动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.